Get the Stockscreener App
54.47
1.11%
-0.535
Corcept Therapeutics Inc stock is traded at $54.47, with a volume of 134.34K.
It is down -1.11% in the last 24 hours and down -26.11% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
See More
Previous Close:
$55.00
Open:
$55.29
24h Volume:
134.34K
Relative Volume:
0.14
Market Cap:
$5.75B
Revenue:
$628.56M
Net Income/Loss:
$141.82M
P/E Ratio:
43.23
EPS:
1.26
Net Cash Flow:
$142.60M
1W Performance:
+0.17%
1M Performance:
-26.11%
6M Performance:
+42.72%
1Y Performance:
+124.75%
1-Day Range:
$54.30
$55.55
1-Week Range:
$52.45
$57.95
52-Week Range:
$20.84
$75.00
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
54.35 | 5.75B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.76 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.32 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
579.12 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.63 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.04 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
Corcept therapeutics director sells $117,920 in stock - Investing.com
Corcept trial to evaluate Cushing’s and hypertension - Cushing's Disease News
Head-To-Head Review: Corcept Therapeutics (NASDAQ:CORT) vs. Ocular Therapeutix (NASDAQ:OCUL) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Corcept Therapeutics Incorporated (CORT) Shareholders to Inquire about Securities Investigation - Markets Insider
Before You Invest, Make Sure You Check This Corcept Therapeutics Inc (NASDAQ: CORT) Analysis - Stocks Register
Corcept Therapeutics Stock Surges Amid Clinical Trial News - TipRanks
Corcept Therapeutics launches study on link between high cortisol and resistant hypertension - Marketscreener.com
Corcept Therapeutics initiates Momentum trial to treat resistant hypertension - TipRanks
Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension - StockTitan
Bank of New York Mellon Corp Has $29.72 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept's NDA for its hypercortisolism treatment gets FDA nod - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Corcept Therapeutics Incorporated (CORT) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
Corcept Shares Rise More Than 55% in 6 Months: Here's Why - Nasdaq
Are Options Traders Betting on a Big Move in Corcept Therapeutics (CORT) Stock? - Nasdaq
Corcept Therapeutics Incorporated (CORT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
CORT's Q4 Earnings and Revenues Fall Short of Estimates - MSN
Corcept Therapeutics president sells over $1.1 million in stock By Investing.com - Investing.com South Africa
FDA decision on relacorilant for Cushing’s expected by year’s end - Cushing's Disease News
Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Investors to Connect - Markets Insider
Corcept Therapeutics' (NASDAQ:CORT) Earnings Offer More Than Meets The Eye - Yahoo Finance
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks - The Globe and Mail
Corcept Therapeutics president sells over $1.1 million in stock - Investing.com
Corcept Therapeutics CEO Joseph Belanoff sells $178,097 in stock By Investing.com - Investing.com South Africa
Corcept Therapeutics executive sells $1.18 million in stock - Investing.com
Corcept Therapeutics CEO Joseph Belanoff sells $178,097 in stock - Investing.com India
Corcept Therapeutics executive sells $1.18 million in stock By Investing.com - Investing.com UK
Corcept: Turning A Corner, But Risks Remain (NASDAQ:CORT) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Encourages Corcept Therapeutics Incorporated (CORT) Stockholders to Inquire about Securities Investigation - Markets Insider
Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025 - MSN
Corcept Therapeutics: Strong Buy Rating Driven by NDA Acceptance and Promising Trial Outcomes - TipRanks
Corcept Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Corcept therapeutics officer sells $277,901 in stock - Investing.com
Corcept Therapeutics Says New Drug Application for Cushing's Syndrome Treatment Filed by FDA - Marketscreener.com
FDA sets December 30, 2025 PDUFA date for Corcept drug - Investing.com
FDA files Corcept’s NDA for Relacorilant as treatment in Hypercortisolism - TipRanks
FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism - Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics IncorporatedCORT - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Corcept Therapeutics Incorporated (CORT) and Encourages Investors to Learn More About the Investigation - Markets Insider
HC Wainwright Issues Pessimistic Estimate for CORT Earnings - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Corcept Therapeutics Incorporated (CORT) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
HC Wainwright Issues Positive Outlook for CORT Earnings - Defense World
Corcept Therapeutics (NASDAQ:CORT) Rating Lowered to Hold at StockNews.com - Defense World
Illumine Investment Management LLC Invests $1.03 Million in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Wakefield Asset Management LLLP Takes Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
QRG Capital Management Inc. Purchases 6,163 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Versor Investments LP Sells 12,600 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Piper Sandler Raises Corcept Therapeutics (NASDAQ:CORT) Price Target to $78.00 - Defense World
FourThought Financial Partners LLC Purchases New Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
3 Reasons Why Growth Investors Shouldn't Overlook Corcept (CORT) - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Corcept Therapeutics Incorporated (CORT) Investors to Inquire about Securities Investigation - Markets Insider
Why Corcept Therapeutics (CORT) is a Top Growth Stock for the Long-Term - Yahoo Finance
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Corcept Therapeutics Inc Stock (CORT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Swisher Daniel N JR | Director |
Mar 10 '25 |
Sale |
53.60 |
2,200 |
117,920 |
0 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):